49 POSTER Analyses of pharmacodynamic (PD) assessments collected during expanded cohorts (EC) of a phase I trial with OSI-930, a multi-targeted oral tyrosine kinase inhibitor (TKI)
J. Spratlin, H.T. Arkenau, S. George, N.J. Serkova, M. Germuska, K. Brock, R. Gedrich, M. Scurr, G.D. Demetri, D.R. CamidgeVolume:
6
Year:
2008
Language:
english
DOI:
10.1016/s1359-6349(08)71981-5
File:
PDF, 58 KB
english, 2008